Close menu

May 14th, 2024 | 07:30 CEST

Bayer, Defence Therapeutics, Novavax - Major events

  • Biotechnology
  • Pharma
Photo credits:

The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Novavax - Share price doubles out of nowhere

    Amid the COVID-19 pandemic, the US-based pharmaceutical company specializing in vaccine development was on par with vaccine producers like BioNTech or Moderna. However, after peaking at USD 331 in February 2021, the Novavax vaccine experienced a sharp decline following several postponements. Last Thursday, the share price fell by over 98% to USD 4.50.

    The Company from Gaithersburg, Maryland, made an impressive comeback with a bang and a share price increase of over 100%. A license agreement was signed with the French pharmaceutical giant Sanofi to market a combined COVID-19 and flu vaccine. Marketing is set to begin as early as next year.

    The license agreement allows Novavax to withdraw the warning issued in February 2023 regarding the Company's viability. One aspect of the agreement will enable Sanofi to use the COVID-19 vaccine technology, including the Matrix-M adjuvant, for the development of new vaccine products. Sanofi will make an upfront payment of USD 500 million to Novavax and additionally pay up to USD 700 million based on the achievement of certain development, regulatory, and launch milestones.

    In addition, Sanofi will acquire a stake of less than 5% in Novavax as part of this agreement. This total amount significantly exceeds Novavax's current market capitalization of USD 627 million.

    Defense Therapeutics - New milestone

    The Canadian biotech company Defence Therapeutics, which is researching the development of next-generation vaccines and ADC products based on its scalable and patent-protected platform, recorded a daily increase of 45% from CAD 1.20 to CAD 1.74 in the past trading week amid conspicuously high volumes. Since then, the Company's share price, valued at CAD 59.65 million, has been consolidating in a textbook fashion, which could offer another short-term entry opportunity.

    Defence Therapeutics, whose platform is based on the ACCUM™ technology, which makes it possible to transport vaccine antigens or antibody-drug conjugates (ADCs) precisely to the diseased cells, has been shining with a consistently positive news flow for months. Recently, a successfully completed preclinical test to combat pancreatic cancer was published.

    The vaccine ARM-002™, based on AccuTOX®, an optimization of the ACCUM™ molecule developed by Defence Therapeutics and the associated platform technology, showed exceptionally good results, especially in combination with the anti-PD-1 immune checkpoint inhibitor. According to the Company, these represent a significant milestone and an occasion to specifically target pancreatic cancer in the Phase I study with the ARM-002™ vaccine.

    The pancreatic cancer market is forecast to exceed USD 36 billion by the end of 2036, representing an average annual growth of 18% during the forecast period from 2024 to 2036. In 2023, the market size was over USD 6 billion. If further positive results from Defence Therapeutics follow, the share is likely to face a revaluation.

    Bayer - It will be exciting

    Will the problem child of recent years become the stock market star of 2024? There are increasing signs of a turnaround and the chart picture is improving day by day. The next hurdle Bayer shares overcame was the striking horizontal resistance at EUR 29.35. The fresh buy signal should push the share price into the EUR 36.10 range. The next step will be to close the price gap at EUR 40.66, which was opened in the middle of last November.

    The necessary impetus for a successful interim rally could come as early as today when the pharmaceutical and agricultural giant presents its figures for the first quarter. Analysts are still forecasting a negative trend in sales and earnings, which could trigger a rally in the event of positive surprises.

    The company's management has also already pointed to weaker first months. A "restrained development" is expected, particularly in the Consumer Health and Crop Service segments. Looking at the statements made by Group CEO Bill Anderson, Bayer still expects to achieve its targets for the year as a whole. One of the components is likely to continue to be the progress of the legal disputes regarding glyphosate.

    Bayer broke through a significant technical resistance level. Defense Therapeutics announced a milestone in the fight against pancreatic cancer. The cooperation with Sanofi pulled the Novovax share out of its downward spiral.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.


    Commented by Fabian Lorenz on May 9th, 2024 | 08:00 CEST

    Stocks facing revaluation! Nel ASA, Bayer, Power Nickel with potential

    • Mining
    • Gold
    • Silver
    • Nickel
    • Pharma
    • renewableenergies

    Relief for Bayer. In the US, the Company has won a victory in the dispute over compensation for illnesses caused by the chemical PCB. Is it groundbreaking and the start of a revaluation of the share? A revaluation already seems to be underway at Power Nickel. Following sensational drilling results, the share price soared. Surprisingly, gold, silver and copper were also found. Against this backdrop, the share appears to be favorably valued. Does this also apply to Nel? After all, the share price has risen by around 20% in just a few weeks. Is there new hope for the hydrogen pioneer? Or are today's figures from industry peer Plug Power threatening a new sell-off?


    Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST

    Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list

    • Biotechnology
    • Pharma

    Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.